A 68-year-old shuffles in with a tremor. Is it Parkinson's? Essential tremor? Something else entirely? One question separates them all.
Before any diagnosis, answer: When does the tremor occur?
| Type | When | Diagnosis | Hz |
|---|---|---|---|
| Resting | At rest; stops with movement | Parkinson's disease | 4-6 Hz |
| Action/Postural | During movement or holding posture; absent at rest | Essential Tremor | 6-12 Hz |
| Intention | Worsens as hand approaches target | Cerebellar (MS, stroke) | 3-5 Hz |
Loss of dopaminergic neuronsThese neurons project from substantia nigra → striatum (caudate + putamen). Dopamine normally suppresses unwanted movement. Without it: the basal ganglia circuit can't inhibit movement → tremor, rigidity, bradykinesia. in the substantia nigra pars compacta → ↓dopamine in the nigrostriatal pathway.
Histology: Lewy bodies — intracytoplasmic inclusions of alpha-synucleinAlpha-synuclein is a protein that aggregates abnormally in PD. It's also seen in Lewy body dementia and multiple system atrophy. Boards may test: "eosinophilic intracytoplasmic inclusion bodies" = Lewy bodies = PD.. Eosinophilic, round, concentric rings.
Gross pathology: Loss of pigmentation (neuromelanin) in the substantia nigra. Normal brain is dark there; PD brain is pale.
| Drug | Mechanism | Board Notes |
|---|---|---|
| Levodopa / Carbidopa | L-DOPA (dopamine precursor) + peripheral decarboxylase inhibitor (carbidopa blocks conversion outside CNS) | Gold standard. Most effective. "On-off" phenomenon with long-term use. Dyskinesias at high doses. |
| Dopamine Agonists pramipexole, ropinirole, bromocriptine | Direct D2/D3 agonists | Used as monotherapy in younger patients to delay levodopa and avoid dyskinesias. Side effect: impulse control disorders (gambling, hypersexuality). |
| MAO-B Inhibitors selegiline, rasagiline | Block breakdown of dopamine in the synapse | Neuroprotective? Modest symptomatic effect. Safe add-on. |
| COMT Inhibitors entacapone, tolcapone | Prolong levodopa effect by blocking peripheral COMT | Always used WITH levodopa. Extends "on" time. Tolcapone: hepatotoxicity risk. |
| Anticholinergics benztropine, trihexyphenidyl | Block M receptors to rebalance ACh/DA ratio | Only good for tremor. Useless for bradykinesia. Avoid in elderly → confusion, urinary retention. "Cognitively toxic." |
| Amantadine | NMDA antagonist, increases DA release | Now primarily used to treat levodopa-induced dyskinesias. |
Most common movement disorder (more common than PD). Action/postural tremor — bilateral, affects hands and arms. Absent at rest. Worsens with goal-directed movement (pouring coffee, writing, bringing a spoon to mouth).
Classically improves with alcohol (patients self-medicate — worth knowing). Worsens with caffeine, stress, fatigue.
Familial: Autosomal dominant inheritance in many cases. "My dad and his dad had it." Positive family history is a clue.
Head tremor (titubation) and voice tremor can occur. Head tremor = "no-no" or "yes-yes" oscillation.
If you see these features alongside tremor, reconsider PD or another diagnosis.
| Drug | Notes |
|---|---|
| Propranolol (beta-blocker) | First-line. Non-selective beta-blocker. 50-70% see benefit. Avoid in asthma, COPD, bradycardia. |
| Primidone (anticonvulsant) | First-line alternative. Converted to phenobarbital. Works well. Side effect: initial sedation ("first-dose reaction"). |
| Gabapentin, topiramate | Second-line options. |
| Deep brain stimulation (DBS) | Thalamic VIM nucleus. For refractory ET. Very effective for tremor. |
Autosomal dominant. Trinucleotide CAG repeat expansionCAG encodes glutamine. The huntingtin protein (HTT) with a polyglutamine tract that's too long becomes toxic to neurons, especially in the striatum. Normal: ≤26 repeats. Premutation: 27-35. Disease: ≥36 (reduced penetrance), ≥40 (full penetrance). in the huntingtin gene on chromosome 4. Normal ≤26 repeats. Disease ≥36. Anticipation: more repeats in each generation → earlier onset.
Typically presents age 30-50 years. Insidious onset. Progressive. Fatal within 15-20 years of diagnosis. No disease-modifying treatment.
Atrophy of the caudate nucleus (part of the striatum). Loss of GABA-ergic medium spiny neurons. On MRI: "boxcar ventricles" — the caudate normally bulges into the lateral ventricle; in HD it atrophies and the ventricle widens.
The caudate normally inhibits unwanted movement via the indirect pathway. Without it: uncontrolled, random movement.
| Target | Drug | Notes |
|---|---|---|
| Chorea | Tetrabenazine (vesicular monoamine transporter inhibitor, depletes dopamine) | FDA-approved for HD chorea. Can worsen depression/suicidality — monitor closely. |
| Chorea | Deutetrabenazine | Longer-acting version. Better tolerated. |
| Psychiatric | Antidepressants (SSRIs), antipsychotics (for psychosis/irritability) | Manage symptoms. Standard agents. |
| Disease | Nothing | No neuroprotective or disease-modifying treatment exists. Palliative care focus. Genetic counseling for family members. |
Drugs that block D2 receptorsDopamine D2 receptors in the striatum. Block them pharmacologically → same net effect as losing dopamine neurons → parkinsonism. The key difference: drug-induced is reversible. Primary PD is not. can cause a syndrome identical to PD: bradykinesia, rigidity, tremor.
The culprits (D2 blockers):
Key difference from PD: Reversible when the offending drug is stopped. If you see "parkinsonism" in a patient on metoclopramide or antipsychotics → the first step is discontinue the drug.
Autosomal recessive. Mutation in ATP7B (copper transporter) → copper accumulates in liver, brain, eyes, kidneys.
Board buzzword cluster: Young patient (teens to 40s) + movement disorder (tremor, dysarthria, chorea, or parkinsonism) + liver disease (hepatitis, cirrhosis) + Kayser-Fleischer rings (copper deposition in Descemet membrane of cornea — golden-brown rings at the limbus) = Wilson's until proven otherwise.
Psychiatric: Personality change, depression, psychosis. Can present primarily psychiatric in young patients.
Lab workup: ↓serum ceruloplasminCeruloplasmin is the copper-carrying protein. In Wilson's it's LOW because the liver can't make it (copper accumulation damages hepatocytes). Serum copper may be low (less ceruloplasmin to carry it) but 24-hour urine copper is HIGH (free unbound copper spills into urine). Both tests are used together. (<20 mg/dL), ↑24-hour urine copper, liver biopsy (gold standard).
Treatment: Penicillamine or trientine (copper chelators). Zinc (blocks intestinal copper absorption). Liver transplant for severe hepatic failure.
| Parkinson's | Essential Tremor | Huntington's | |
|---|---|---|---|
| Tremor type | Resting, 4-6 Hz, pill-rolling | Action/postural, 6-12 Hz | Chorea (not tremor) |
| Bradykinesia | YES — cardinal feature | NO | Late (rigidity eventually) |
| Rigidity | YES — cogwheel | NO | Late-stage |
| Genetics | Mostly sporadic; some LRRK2, PARK mutations | Often autosomal dominant; sporadic common | Autosomal dominant, CAG >36 |
| Onset age | 60s-70s (young-onset <50 exists) | Any age; ↑with age | 30-50s |
| Psychiatric sx | Depression, dementia late; DLB overlap | Usually none | FIRST symptom: depression, personality |
| Pathology | Substantia nigra loss; Lewy bodies | Unclear; mild cerebellar changes | Caudate atrophy; huntingtin aggregates |
| Treatment | Levodopa/carbidopa | Propranolol, primidone | None (palliative only) |
| Alcohol effect | No significant change | Improves (classic feature) | No significant change |